(RTTNews) - Idera Pharmaceuticals Inc. (IDRA:
News ) said Novartis will terminate its research collaboration agreement with the company, effective as of February 21, 2010.
Additionally, the company stated that it had recently filed an Investigational New Drug application for IMO-3100 for potential applications in autoimmune diseases.
Also, the company looks forward to outlining strategies for the development of its TLR-targeted compounds for respiratory diseases.
Click here to receive FREE breaking news email alerts for Idera Pharmaceuticals, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: contact editorial@rttnews.com